This project aims to refine NeuroDex’s ExoSORT™ platform, an advanced technology designed to isolate neuron-derived extracellular vesicles (EVs) from blood. In this project we will work with MJFF’s landmark Parkinson's Progression Markers Initiative (PPMI) study to test the accuracy of our ExoSORT based α-Synuclein blood assay to identify patients with positive CSF seeding assay. This work is another step toward development of minimally invasive biomarker for the early diagnosis and staging of Parkinson's disease, which could offer new tool for treatment development and a new hope for earlier and more accurate diagnosis.
Dr. Erez Eitan, President and Chief Scientific Officer of NeuroDex, commented, “We are honored to receive this grant from The Michael J. Fox Foundation and are excited to test our automated ExoSORT platform capabilities as a blood-based biomarker for a-synuclein pathologies. We believe this work with PPMI can help us bring this important biomarker tool to clinical trial and clinical practice faster.”
About NeuroDex Inc.
NeuroDex is a biotechnology company at the forefront of developing exosome-of-origin-based diagnostics, theranostics, and prognostics. Utilizing their proprietary ExoSORT™ technology, NeuroDex aims to create a wide range of minimally invasive diagnostics through bioinformatics and laboratory innovation. For more information, please visit (https://www.neurodex.co).
About Exosomes
Exosomes, or extracellular vesicles, are small, membrane-bound particles released by cells into the extracellular space. They play a critical role in cellular communication and have significant potential as biomarkers for a variety of diseases due to their molecular composition, which reflects their cell of origin.
Forward-Looking Statement Disclaimer
Various statements in this release concerning NeuroDex’s, future expectations, plans and prospects, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors. In addition, any forward-looking statements represent NeuroDex’s views only as of the date of this release and should not be relied upon as representing their views as of any subsequent date. NeuroDex does not assume any obligation to update any forward-looking statements unless required by law.
NeuroDex Contact:
Erez Eitan, President and CSO
